Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand
作者： M. James , A. Dixit , B. Robinson , C. Frampton , V. Davey
DOI: 10.1016/J.CLON.2018.09.006
关键词:
摘要: … The mean tumour size was 23 mm, with 10.5% of all patients with T3/T4 tumour stage and 37.8… non-TNBC. The recurrence in TNBC is more likely visceral and occurs in multiple sites. In …
sci-hub.se 参考文章(21)
J. Kollias, C.W.L. Ooi, P. de Silva, I.D. Campbell, National Breast Cancer Audit: overview of invasive breast cancer in New Zealand. The New Zealand Medical Journal. ,vol. 125, pp. 7- 16 ,(2012)
Monica Fornier, Pierre Fumoleau, The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment Breast Journal. ,vol. 18, pp. 41- 51 ,(2012) , 10.1111/J.1524-4741.2011.01175.X
Monica Morrow, Yun Li, Amy K. Alderman, Reshma Jagsi, Ann S. Hamilton, John J. Graff, Sarah T. Hawley, Steven J. Katz, Access to Breast Reconstruction After Mastectomy and Patient Perspectives on Reconstruction Decision Making JAMA Surgery. ,vol. 149, pp. 1015- 1021 ,(2014) , 10.1001/JAMASURG.2014.548
Stephen B. Edge, Carolyn C. Compton, The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM Annals of Surgical Oncology. ,vol. 17, pp. 1471- 1474 ,(2010) , 10.1245/S10434-010-0985-4
Katrina R. Bauer, Monica Brown, Rosemary D. Cress, Carol A. Parise, Vincent Caggiano, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. ,vol. 109, pp. 1721- 1728 ,(2007) , 10.1002/CNCR.22618
Sandra S. Zaky, MaryJo Lund, Kelly A. May, Karen D. Godette, Jonathan J. Beitler, Leslie R. Holmes, Ruth M. O’Regan, Esther S. Yu, David S. Yu, Jerome C. Landry, The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy. Annals of Surgical Oncology. ,vol. 18, pp. 2858- 2865 ,(2011) , 10.1245/S10434-011-1669-4
Aoife J. Lowery, Malcolm R. Kell, Ronan W. Glynn, Michael J. Kerin, Karl J. Sweeney, Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Breast Cancer Research and Treatment. ,vol. 133, pp. 831- 841 ,(2012) , 10.1007/S10549-011-1891-6
William M. Sikov, Donald A. Berry, Charles M. Perou, Baljit Singh, Constance T. Cirrincione, Sara M. Tolaney, Charles S. Kuzma, Timothy J. Pluard, George Somlo, Elisa R. Port, Mehra Golshan, Jennifer R. Bellon, Deborah Collyar, Olwen M. Hahn, Lisa A. Carey, Clifford A. Hudis, Eric P. Winer, Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) Journal of Clinical Oncology. ,vol. 33, pp. 13- 21 ,(2015) , 10.1200/JCO.2014.57.0572
Patrick Neven, Brouckaert, Wildiers, Floris, Update on triple-negative breast cancer: prognosis and management strategies. International Journal of Women's Health. ,vol. 4, pp. 511- 520 ,(2012) , 10.2147/IJWH.S18541
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N Hortobagyi, Lajos Pusztai, None, Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1275- 1281 ,(2008) , 10.1200/JCO.2007.14.4147